Table 3. Univariate analysis and multivariate analysis of prognostic factors.
| Variable | Univariate analysis | Multivariable analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age at primary treatment (≤60 vs. >60 y) | 0.266 (0.063–1.125) | 0.357 | |||
| Sex (male vs. female) | 0.266 (0.063–1.125) | 0.072 | 0.301 (0.071–1.277) | 0.103 | |
| BMI (kg/m2) | |||||
| 18.5–23.9 vs. <18.5 | 0.935 (0.345–2.540) | 0.896 | |||
| ≥24 vs. <18.5 | 0.823 (0.260–2.611) | 0.741 | |||
| Tumor location | |||||
| Middle third vs. proximal third | 1.369 (0.411–4.561) | 0.610 | |||
| Distal third vs. proximal third | 0.863 (0.173–4.302) | 0.857 | |||
| Clinical T stage | |||||
| cT3 vs. cT2 | 0.834 (0.303–2.295) | 0.725 | |||
| cT4 vs. cT2 | 1.182 (0.386–3.619) | 0.770 | |||
| Clinical N stage (N0 vs. N1) | 1.375 (0.325–5.809) | 0.665 | |||
| Clinical stage group (IIB vs. III) | 0.929 (0.353–2.444) | 0.881 | |||
| Cycles of chemotherapy (1 vs. 2) | 1.229 (0.291–5.188) | 0.779 | |||
| Interval between the end of NCRT and surgery (≤6 vs. >6 weeks) | 0.596 (0.278–1.274) | 0.181 | |||
| Number of lymph nodes dissected (≤19 vs. >19) | 0.428 (0.202–0.910) | 0.027 | 0.521 (0.243–1.118) | 0.094 | |
| Positive lymph nodes dissected (no vs. yes) | 5.316 (2.453–11.525) | 0.000 | 4.757 (2.195–10.313) | 0.000 | |
BMI, body mass index; NCRT, neoadjuvant chemoradiotherapy.